Choosing the Acid for the Acne Patient
A decision framework for matching the peeling acid to the acne patient — salicylic for oily, comedonal and inflammatory disease; mandelic for darker, reactive or PIH-prone skin; glycolic for texture in lighter skin — sorted by lesion type, oiliness and pigmentation risk.
The right peel for an acne patient is the one whose chemistry matches the lesion type, the oiliness and — critically in Fitzpatrick IV–VI — the pigmentation risk. There is no single "best acne acid": salicylic acid owns the oily, comedonal and inflammatory picture because it is lipophilic and reaches the follicle; mandelic acid owns darker, reactive and PIH-prone skin because its large molecule penetrates slowly and evenly with low irritation; glycolic acid earns a place for surface texture in lighter, less reactive skin but penetrates fast and unevenly. This lesson gives you the decision logic and a table to apply it at the chairside.
The three acids, by what they actually do
Each acid sits in a different compartment and carries a different risk profile. Pick on mechanism, not marketing.
The single most useful distinction is lipophilic vs hydrophilic. Salicylic acid is oil-soluble and goes into the follicle, so it treats the cause of comedonal and inflammatory acne. Glycolic and mandelic are water-soluble AHAs that act mainly at the surface, improving texture, tone and superficial pigment — useful, but not follicular. Among the AHAs, molecular size then decides reactivity: mandelic's larger molecule penetrates slowly and evenly (forgiving), glycolic's small molecule penetrates fast and unevenly (effective but less forgiving in darker skin).
The decision table
Read it by the patient's dominant feature — lesion type first, then oiliness and skin type.
| Patient picture | First-choice acid | Why | Caution |
|---|---|---|---|
| Comedonal, congested, very oily | Salicylic | Lipophilic; clears follicular plugs, regulates sebum | Watch barrier if already on drying topicals |
| Inflammatory papulopustular acne | Salicylic (± azelaic in tri-acid) | Anti-inflammatory + comedolytic | Peel intact skin only; pause in open-lesion flares |
| Acne in Fitzpatrick IV–VI / PIH-prone | Mandelic-forward | Even, low-irritation penetration → lowest PIH risk | Build depth across a series, not one session |
| Reactive / sensitive acne skin | Mandelic | Most forgiving penetration profile | Avoid stacking with aggressive home actives |
| Surface texture / tone in lighter skin | Glycolic | Fast surface turnover | Uneven penetration; higher PIH risk in IV–VI |
| Acne + significant erythema / rosacea overlap | Azelaic-led | Antimicrobial + anti-inflammatory, calms redness | Confirm diagnosis before treating |
| Mixed picture, one mechanism insufficient | Tri-acid combo | Follicular + surface action together | Titrate to tolerance |
The logic underneath the table is simple. Lesion type chooses the compartment (follicular plugs and inflammation → salicylic; surface texture and tone → an AHA). Skin type then chooses among the AHAs: mandelic for IV–VI and reactive skin, glycolic for lighter, robust skin. And whenever pigmentation risk is high, that consideration overrides — bias toward mandelic-forward chemistry even if a glycolic peel might technically resurface faster, because a fast peel that triggers PIH sets the patient back months.
When one acid is not enough
Real acne is rarely pure. A patient with oily, comedonal skin who is also Fitzpatrick V needs both follicular targeting and a low-PIH-risk penetration profile — which is exactly why combination tri-acid systems exist. Pairing a lipophilic BHA (salicylic) for the follicle with a large-molecule AHA (mandelic) for even, low-irritation surface action lets you treat the acne and respect the pigmentation risk in one protocol, rather than forcing a single-agent compromise.
Key takeaway
Match the acid to the patient. Salicylic acid is the default for oily, comedonal and inflammatory acne because it is lipophilic and reaches the follicle. Mandelic acid is the safest choice for Fitzpatrick IV–VI, reactive and PIH-prone skin because its large molecule penetrates slowly and evenly. Glycolic acid earns a place for surface texture in lighter, robust skin but penetrates unevenly and carries more PIH risk in darker skin. When the picture is mixed — oily and dark — reach for a mandelic-led tri-acid that combines follicular and surface action while keeping the pigmentation risk low. Lesion type chooses the compartment; skin type chooses the AHA; pigmentation risk overrides.
Frequently asked questions
Salicylic or glycolic for acne — which is better?
For acne specifically, salicylic acid is usually the better first choice because it is lipophilic and partitions into the sebaceous follicle where acne begins, giving it comedolytic and anti-inflammatory action on the actual lesions. Glycolic acid is a water-soluble AHA that works mainly at the surface, so it improves texture and tone but does not target the follicle. Glycolic also penetrates fast and unevenly, which raises the PIH risk in darker skin. Use glycolic for surface texture in lighter, robust skin and salicylic for the acne itself.
Why choose mandelic acid for acne in darker skin?
Because pigmentation risk, not acne grade alone, is the deciding variable in Fitzpatrick IV–VI. Mandelic acid's larger molecule penetrates slowly and uniformly with low irritation, and since inflammation is the upstream trigger of post-inflammatory hyperpigmentation, a low-irritation peel buys the largest safety margin. It also has mild antibacterial activity. That makes mandelic — or a mandelic-led tri-acid — the most defensible acne peel in reactive or PIH-prone skin, even when a glycolic peel might resurface faster.
When should I use a combination tri-acid peel instead of a single acid?
When one mechanism is not enough. A patient who is oily and comedonal and darker-skinned needs both lipophilic follicular targeting and a low-PIH-risk penetration profile; a single agent forces a compromise. A tri-acid that pairs salicylic (follicular) with mandelic (even, low-irritation surface action) treats the acne and respects the pigmentation risk in one protocol. Titrate combinations to tolerance and escalate only after the skin shows it tolerates the first sessions cleanly.
Does the acid choice change with acne severity?
The acid choice handles superficial, follicular disease — comedonal and mild-to-moderate inflammatory acne. As severity rises into nodulocystic or scarring disease, the answer is not a stronger acid but systemic medical therapy; peeling is an adjunct, not a substitute. Within the peelable range, escalate by combining mechanisms (single salicylic → tri-acid) and by titrating strength to tolerance, while keeping pigmentation risk in view for Fitzpatrick IV–VI.
